ARCHIVES

$1.5 Million In Direct Costs Is Proposed Core Grant Requirement

This article is from The Cancer Letter archive.

Vol. 17 No. 28 | July 12, 1991

Download PDF Visit The Full Archive

Related Articles

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

October 31, 2014

Centers Form Big Ten Research Consortium with Access to Over 30,000 New Patients a Year

May 31, 2013

FDA Clears Rapid Test For Aspergillus Infection

May 30, 2003

Congress Approves More Favorable Terms for Office-Administered Drugs

August 8, 1997

Cancer Control Dilemma: What To do With Successful Demonstrations

September 10, 1976

NCI Study Fails To Support Finding Of Excess Cancer In Utah Nuclear Fallout Areas

January 23, 1987